3-Chloro-D-Alanine Methyl Ester Hydrochloride

112346-82-4

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orγiented and realizes industrial development through R&D innovation a≥nd technology transformation.

key word:

Pharmaceutical innovative

Category:

Intermediate

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health≤ industry finance platform company integrating pharmaceutΩical, intelligent medical, bio pharmaceutical R&D, in☆dustrial production and sales.

The chemical reactions involved in the existing products include Fou♠cault reaction, nitration reaction, sulfonation reaction, hydrogenation reaction, flu₹orination reaction, chlorination reaction, bromination reaction, diazotization r€eaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor dev↓eloped by Merck. In October 2006, Sitagliptin phosphate Januvia w↓as approved by FDA as the first DPP4 inhibitor for the treσatment of type ⅱ diabetes mellitus. The characteristics of this drug are t&hat it can stimulate insulin secretion while reducing hunger without causing weight£ gain. Hypoglycemia and edema will not occur, and it is suitable for diabetic patients wi£th poor blood glucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterpr≥ise that is market-oriented and realizes industria™l development through R&D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important products for theφ treatment of arthritis. It is well tolerated and ha∞s a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major l÷eukotriene receptor antagonists. In clinical application, it has good therapeutic effect on atop₩ic asthma and other types of bronchial asthma, and the market pro¥spect is huge. In the major category of asthma drugs, leukotriene receptor a∞ntagonists have the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmγaceutical enterprise that is market-oriented and re§alizes industrial development through R&D innovation and teλchnology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It isπ the second drug approved by FDA for Alzheimer's disease in the United States.≤ Its treatment reaches the target dose and has low toxiλc and side effects. It has been widely recognized by♥ our medical community, and good tolerance is its bβiggest advantage. In October 1999, Donepezil was launched in China under the trade na≠me "Aricept", which is the main chemical drug against Alzheimer's disease. At p→resent, CFDA has approved a number of domestic entλerprises to produce donepezil preparations, the main dosage forms are tablets, capsules, dis persive tablets, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Mye←rs Squibb/Pfizer), a direct oral factor Xa inhibitor, was approved for use in the 27 EU member ✔states. The world's first drug approved to prevent venous thromboembo‍lism (VTE) in adult patients undergoing elective hip o↑r knee replacement. From June 2019 to June 2020, the annual sales of apixab•an products overseas reached about $15.4 billion, with a year-on-year growth of nearl✔y 32%, and the API consumption reached about 23,960 kg, with a year-o♦n-year growth of about 28%. Compared with its main compe↑titor, Rivaroxaban, the drug's annual overseas sales are about $4.5 §billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceuticaσl enterprise that is market-oriented and realizes industrial development through R&D innovat÷ion and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. On  December 29, 2004, it was approved by FDA for the treatment of r♦efractory or relapsed acute lymphoblastic leukemia (ALL) in childreβn.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmac♥eutical enterprise that is market-oriented and realizes industrial development t hrough R&D innovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other services, E-mail₩: 2880705932@qq.com
Submit